key: cord-0881250-aqvgrb2d
authors: Hirshberg, Jonathan S.; Cooke, Emily; Oakes, Megan C.; Odibo, Anthony O.; Raghuraman, Nandini; Kelly, Jeannie C.
title: Monoclonal antibody treatment of symptomatic COVID-19 in pregnancy: Initial report
date: 2021-08-25
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2021.08.025
sha: b7d1b3a3049f792bdcd1c2b44534b2e0f5ee0d22
doc_id: 881250
cord_uid: aqvgrb2d

nan

J o u r n a l P r e -p r o o f to reduce disease progression and hospitalization in those at high-risk for disease progression [1] . The 32

United States Food and Drug Administration provided emergency use authorization (EUA) for 33 neutralizing mAbs in November of 2020, which included a warning for pregnant and lactating women. 34

Mounting evidence that COVID-19 has a disproportionate effect on pregnant women, with higher rates In this case series of maternal mAb therapy in pregnancy, we found no evidence of pregnancy 68 complications or treatment failure. All four patients avoided progression to severe disease and none 69 required additional COVID-19 related medical visits or hospitalizations. Anti-spike protein neutralizing 70 antibodies are human IgG1κ with unadulterated FC receptors, which should allow for facilitated 71 diffusion across the placenta [4], raising the concern for transplacental passage. However, there were 72 no fetal effects noted in our small cohort. Given the ongoing severity of the COVID-19 pandemic, 73 especially in pregnancy, more information regarding the safety and efficacy of neutralizing mAbs in 74 pregnancy is vital. 75 J o u r n a l P r e -p r o o f 

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Update: Characteristics of Symptomatic Women of Reproductive Age with 84

SARS-CoV-2 Infection by Pregnancy Status -United States

Fact sheet for healthcare providers: emergency use authorization (EUA) of REGEN-COV 87 (casirivimab and imdevimab). Food and Drug Administration

Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal 90 and Fetal Factors. Front Immunol, 2020. 11: p. 1920. 91 5. Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) OF BAMLANIVIMAB